Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon, Yeon Jeong Kim, Joon Ho Shim, Donghyun Park, Junhun Cho, Young Hyeh Ko, Woong Yang Park, Yeung Chul Mun, Kyoung Eun Lee, Duck Cho, Won Seog Kim, Seok Jin Kim

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Purpose Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL. Materials and Methods Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018. Results Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment. Conclusion The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.

Original languageEnglish
Pages (from-to)597-612
Number of pages16
JournalCancer Research and Treatment
Issue number2
StatePublished - Apr 2022

Bibliographical note

Publisher Copyright:
© 2022 by the Korean Cancer Association.


  • Circulating tumor DNA
  • Primary CNS lymphoma
  • Prognosis


Dive into the research topics of 'Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma'. Together they form a unique fingerprint.

Cite this